Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Carbonxt Group - March 2022 Quarterly Activities Report (ASX:CG1)

* Quarterly customer receipts of A$3.8m. However, a further $1.0m of receipts were subject to a logistics delay beyond our control and therefore revenue will be recognised in the next quarter. This ...read more

Carbonxt Group - Appendix 4C (ASX:CG1)

To view the Quarterly cash flow report for entities subject to Listing Rule 4.7B, download the attached PDF.

CARETEQ - 3Q-FY22 Activities Report & Appendix 4C (ASX:CTQ)

Highlights: * Careteq achieves several milestones in the quarter and advances on significant opportunities in Australia and North America, as highlighted in Careteq’s prospectus * Further ...read more

CARETEQ - Clarification of Appendix 3X & Appendix 3Y - M Simari (ASX:CTQ)

Careteq Limited (ASX: CTQ, “Careteq” or the “Group”) advises the following in relation to the Appendix 3X as lodged for Mr Simari on 11 January 2022: * The Appendix 3X was...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31...read more

Careteq & RMIT sign Research Collaboration Agreement (ASX:CTQ)

Highlights: * Leading Victorian university RMIT University will work with Careteq to develop new assistive living technology solutions to expand on Careteq’s proprietary Sofihub platform *...read more

Chimeric Therapeutics - Strategic manufacturing partnership with WuXi ATU (ASX:CHM)

* Global contract testing and manufacturing organization WuXi Advanced Therapies (WuXi ATU) to support Chimeric CAR T cell programs * Enables Chimeric to accelerate manufacturing readiness for its ...read more

CARETEQ - Executive Leadership Team Restructured For Growth (ASX:CTQ)

Careteq Limited (ASX:CTQ, "Careteq" or the "Group") is pleased to announce the restructuring of the executive leadership team to better take advantage of the many growth opportun...read more

Chimeric Therapeutics - Security Class Reinstatement to Quotation CHMO (ASX:CHM)

The suspension of trading in the options (ASX: CHMO) of Chimeric Therapeutics Limited (‘CHM’) will be lifted immediately. For more information, download the attached PDF.

Chimeric Therapeutics - Placement of Entitlement Offer Shortfall (ASX:CHM)

On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) announced the details of an accelerated non-renounceable 1 for 3.15 entitlement offer (Entitlement Offer). Chime...read more

Chimeric Therapeutics - CDH17 CAR T preclinical data featured in Nature Cancer (ASX:CHM)

-- A CAR T targeting the cell surface marker CDH17 (“CDH17 CAR”), currently under development by Chimeric as CHM 2101, is featured in the prestigious journal Nature Cancer, highlighting ...read more

Chimeric Therapeutics - Trading Halt (ASX:CHM)

The securities of Chimeric Therapeutics Limited (‘CHM’) will be placed in trading halt at the request of CHM, pending it releasing an announcement. Unless ASX decides otherwise, the secu...read more

Chimeric Therapeutics - Pause in Trading (ASX:CHM)

Trading in the securities of the entity will be temporarily paused pending a further announcement. For more information, download the attached PDF.

Chimeric Therapeutics - Completion of retail component of Entitlement Offer (ASX:CHM)

On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) announced the details of an accelerated non-renounceable entitlement offer (Entitlement Offer) to raise approximate...read more

Chimeric Therapeutics - Security Class Suspension from Quotation CHMO (ASX:CHM)

The options (ASX: CHMO) of Chimeric Therapeutics Limited (‘CHM’) will be suspended immediately, in accordance with Listing Rule 17.3, as deferred settlement trading will not be made avai...read more

Viewing: 1 - 15 of 200 Previous | Next